Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study.

De Vita F, Borg C, Farina G, Geva R, Carton I, Cuku H, Wei R, Muro K.

Future Oncol. 2019 Jun 25. doi: 10.2217/fon-2019-0243. [Epub ahead of print]

2.

Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer.

Roviello G, Conter FU, Mini E, Generali D, Traversini M, Lavacchi D, Nobili S, Sobhani N.

Cancer Chemother Pharmacol. 2019 Jun 11. doi: 10.1007/s00280-019-03887-2. [Epub ahead of print] Review.

PMID:
31187168
3.
4.

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.

Di Bartolomeo M, Niger M, Morano F, Corallo S, Antista M, Tamberi S, Lonardi S, Di Donato S, Berardi R, Scartozzi M, Cardellino GG, Di Costanzo F, Rimassa L, Luporini AG, Longarini R, Zaniboni A, Bertolini A, Tomasello G, Pinotti G, Scagliotti G, Tortora G, Bonetti A, Spallanzani A, Frassineti GL, Tassinari D, Giuliani F, Cinieri S, Maiello E, Verusio C, Bracarda S, Catalano V, Basso M, Ciuffreda L, De Vita F, Parra HS, Fornaro L, Caporale M, de Braud F, Pietrantonio F.

BMC Cancer. 2019 Mar 29;19(1):283. doi: 10.1186/s12885-019-5498-3.

5.

Evaluation of the safety of ramucirumab in Japanese patients with advanced gastric cancer.

Iwai M, Ito D, Asano H, Adachi S, Okada K, Kimura M, Usami E, Matsuo K, Yoshimura T, Teramachi H.

Pharmazie. 2018 May 1;73(5):309-312. doi: 10.1691/ph.2018.7355.

PMID:
29724300
6.

Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW.

Muro K, Cho JY, Bodoky G, Goswami C, Chao Y, Dos Santos LV, Shimada Y, Topuzov E, Van Cutsem E, Tabernero J, Zalcberg J, Chau I, Cascinu S, Cheng R, Hsu Y, Emig M, Orlando M, Fuchs C.

J Gastroenterol Hepatol. 2018 Apr;33(4):814-824. doi: 10.1111/jgh.14007. Epub 2018 Feb 1.

PMID:
28960444
7.

Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer.

Tabernero J, Ohtsu A, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Ajani JA, Tomasek J, Safran H, Chandrawansa K, Hsu Y, Heathman M, Khan A, Ni L, Melemed AS, Gao L, Ferry D, Fuchs CS.

Mol Cancer Ther. 2017 Oct;16(10):2215-2222. doi: 10.1158/1535-7163.MCT-16-0895. Epub 2017 Jul 17.

8.

Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

B├╝y├╝kkaramikli NC, Blommestein HM, Riemsma R, Armstrong N, Clay FJ, Ross J, Worthy G, Severens J, Kleijnen J, Al MJ.

Pharmacoeconomics. 2017 Dec;35(12):1211-1221. doi: 10.1007/s40273-017-0528-y. Review.

9.

Exposure-response relationship of ramucirumab in East Asian patients from RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.

Kim TY, Yen CJ, Al-Batran SE, Ferry D, Gao L, Hsu Y, Cheng R, Orlando M, Ohtsu A.

Gastric Cancer. 2018 Mar;21(2):276-284. doi: 10.1007/s10120-017-0737-2. Epub 2017 Jun 20.

PMID:
28634748
10.

Second-line chemotherapy for patients with advanced gastric cancer.

Takahari D.

Gastric Cancer. 2017 May;20(3):395-406. doi: 10.1007/s10120-017-0707-8. Epub 2017 Mar 4. Review.

PMID:
28260227
11.

Advanced gastric adenocarcinoma: optimizing therapy options.

Mizrak Kaya D, Harada K, Shimodaira Y, Amlashi FG, Lin Q, Ajani JA.

Expert Rev Clin Pharmacol. 2017 Mar;10(3):263-271. doi: 10.1080/17512433.2017.1279969. Epub 2017 Feb 3. Review.

PMID:
28094573
12.

The safety and efficacy of ramucirumab in combination with paclitaxel for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma.

Garrido M.

Expert Rev Anticancer Ther. 2016 Oct;16(10):1005-10. doi: 10.1080/14737140.2016.1231576. Epub 2016 Sep 14. Review.

PMID:
27582051
13.

Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma.

Davidson M, Smyth EC, Cunningham D.

Onco Targets Ther. 2016 Jul 25;9:4539-48. doi: 10.2147/OTT.S84153. eCollection 2016. Review.

14.

Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma.

Al-Batran SE, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov ON, Kim TY, Cunningham D, Rougier P, Muro K, Liepa AM, Chandrawansa K, Emig M, Ohtsu A, Wilke H.

Ann Oncol. 2016 Apr;27(4):673-9. doi: 10.1093/annonc/mdv625. Epub 2016 Jan 7.

15.

Systemic therapy beyond first-line in advanced gastric cancer: An overview of the main randomized clinical trials.

Galdy S, Cella CA, Spada F, Murgioni S, Frezza AM, Ravenda SP, Zampino MG, Fazio N.

Crit Rev Oncol Hematol. 2016 Mar;99:1-12. doi: 10.1016/j.critrevonc.2015.09.004. Epub 2015 Nov 30. Review.

PMID:
26697987
16.

Ramucirumab: A Review in Advanced Gastric Cancer.

Greig SL, Keating GM.

BioDrugs. 2015 Oct;29(5):341-51. doi: 10.1007/s40259-015-0138-1. Review.

PMID:
26341713
17.

Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer.

Muro K, Oh SC, Shimada Y, Lee KW, Yen CJ, Chao Y, Cho JY, Cheng R, Carlesi R, Chandrawansa K, Orlando M, Ohtsu A.

J Gastroenterol Hepatol. 2016 Mar;31(3):581-9. doi: 10.1111/jgh.13153.

PMID:
26317322
18.

FDA Approval Summary: Ramucirumab for Gastric Cancer.

Casak SJ, Fashoyin-Aje I, Lemery SJ, Zhang L, Jin R, Li H, Zhao L, Zhao H, Zhang H, Chen H, He K, Dougherty M, Novak R, Kennett S, Khasar S, Helms W, Keegan P, Pazdur R.

Clin Cancer Res. 2015 Aug 1;21(15):3372-6. doi: 10.1158/1078-0432.CCR-15-0600. Epub 2015 Jun 5.

19.

Ramucirumab: targeting angiogenesis in the treatment of gastric cancer.

Smyth EC, Tarazona N, Chau I.

Immunotherapy. 2014;6(11):1177-86. doi: 10.2217/imt.14.85. Review.

PMID:
25496333
20.

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A; RAINBOW Study Group.

Lancet Oncol. 2014 Oct;15(11):1224-35. doi: 10.1016/S1470-2045(14)70420-6. Epub 2014 Sep 17.

PMID:
25240821

Supplemental Content

Loading ...
Support Center